Healthcare Startups funded by Y Combinator (YC) 2024

Ginkgo Bioworks is the organism company. We design custom organisms for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.

We make oral drugs to treat and prevent viral infections - like COVID-19.

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

Clipboard Health exists to lift as many people up the socioeconomic ladder as possible. We dramatically improve lives by letting healthcare professionals turn extra time and ambition into career growth and financial opportunity. We achieve this with our app-based marketplace that connects healthcare facilities and healthcare professionals, allowing healthcare professionals to book on-demand shifts and healthcare facilities to access on-demand talent. Our mission is to enable healthcare professionals to work when and where they want and to enable healthcare facilities to meet their talent needs. Clipboard Health is a fast-growing Series C startup with classic two-sided network effects. We have product-market fit, generate substantial revenue, and we are helping nurses fix healthcare one shift at a time. Clipboard Health is a diverse and inclusive company with a global, remote-first team of hundreds of people. We’ve been featured on YC’s Top Companies and grown our revenue 25x in the last 18 months. We need your help to keep growing so we can serve more healthcare professionals, healthcare facilities, and patients.

Blueberry Medical provides concierge pediatric care with at-home medical diagnostics and an always-available team of Pediatricians. Blueberry handles twice as may illnesses as any other telemedicine provider and has proven to reduce ER costs by 50%.

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.

We're a SaaS company with emphasis on Service, and we have a mission: to improve the happiness of scientists and the quality of their research. HappiLabs provides a service called the Virtual Lab Manager. We offer PhD level, former scientists to help with safety and regulatory, product research, lab shopping, negotiating, purchasing, inventory, and bookkeeping. Our software tools, such as the ETA Dashboard and the HappiApp, make it easy to request purchases, manage inventory, and check-in packages upon delivery. HappiLabs also has one of the most extensive databases of product prices. These tools, and experienced humans, make us the smartest lab managers in the world. Another way to think of us is an outsourced purchasing department and/or a personal assistant for your scientists. Based in Chicago, and some presence in San Francisco. If you're a newly funded PI, a startup, small biotech, or work with purchasing as a big pharma/biotech, you can use our help.

Scanbase makes it easy for medical companies to convert photos of rapid diagnostic tests into results. We do this by providing a simple API that any medical company can access.

If we've learned anything in the last few years it's that spending time with our friends and family is essential to our well-being and happiness. Unfortunately, loud and noisy places like weddings and family gatherings hinder human connection, especially for the hearing impaired. In fact, the biggest unmet need in the entire hearing healthcare industry is hearing in noisy places. AudioFocus helps patients hear in these environments by only enhancing voices nearby the patients and ignoring ones farther away. We do this using acoustics informed machine learning and custom microphone array design. Our goal is to increase the adoption rate of 37M US adults with hearing loss, only 8M use hearing aids today. Founded by Auditory Neuroscientist & AI expert and a Hearing Aid hardware design expert.

Chronic pelvic pain is a debilitating condition, that impacts over 15 million US women and costs over $39 Billion each year to manage. V-Flow medical has developed a trio of products that target the root cause of chronic pelvic pain, allowing millions of women to avoid opioid use and restart living a normal, pain free life. The V-Flow team has successfully scaled, multiple start-up medical device companies in various clinical disciplines with a combined exit value of over $4B. We have developed a broad IP portfolio covering both device design and method of application. A recent landscaping identified no competing IP for our indication of use. We have tested our beta prototypes and are initiating animal models ahead of a planned first in human investigation in Q1 2023. Following discussion with the NIH program advisors, we have been encouraged to apply for a phase 1 grant, call to action for the Heal initiative to find new diagnostic and non-drug treatments for chronic pelvic pain.

Subscription model pharmacy for patients with chronic diseases in Latin America. We delivery medicine every month and help with the insurance reimbursement. We're currently operating in Mexico.

India’s insurance market is filled with bygone products, which do not cater to 95% of the market's demand for specific products such as illness-specific insurance, primary care with insurance, and surgical insurance to name a few. We, at IMT, aim to target this white space by creating innovative products that fulfill this new demand by empowering the agents. Agents are the largest insurance distribution channel in India and cover 85% of the premium collection. Agents collect 20B premium every year. With a 5% take rate, it’s a 1B dollar market opportunity growing at 22% CAGR. Kunal has 15+ years of experience working with insurance companies and building agent networks, while he scaled his brokerage business to 3M dollars in revenue. Rachit has 12+ years of experience in building tech products, he was a founding engineer at Payu (stripe of India).

Formerly known as Patchd Medical Wearable technology and AI to predict and prevent sepsis outside of hospital.

Kivo Health provides telehealth rehab for chronic lung disease patients. We offer an 8-week clinical program led by a live therapist, which saves payers $6,000 per patient. Only 3% of eligible patients are getting this life-changing therapy right now.

Kernal Bio creates mRNA 2.0 therapies that instruct specific cells on how to make their own medicine. Kernal Bio encrypts mRNA’s “message” in a language that only cancer cells understand. These tumor-specific mRNA therapeutics allow precise targeting of cancer cells, without harming normal cells or tissues. They have recently been validated in preclinical tumor models, showing high efficacy and safety as well as durable adaptive immunity. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President, Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. VP of BD, Matt Strout, M.D. Ph.D., M.B.A, is a business development executive who led more than $4.5B worth of BD deals at Alexion and AstraZeneca. VP of R&D Manfred is a leader in immuno-oncology, who was most recently Scientific Senior Director at Bristol-Myers Squibb (BMS).

ReleviumBio is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. My co-founder and I are Chemists with PhDs in Biomedical Engineering and we have an experienced leadership team already in place. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.

Metriport helps healthcare organizations access and manage comprehensive patient medical data. Through a single integration, Metriport ensures clinical accuracy and completeness of medical information to providers, delivering comprehensive consolidated patient clinical data at the point-of-care. By standardizing, de-duplicating, consolidating, and hydrating the data with medical code crosswalking, providers get a rich understanding of their patients' medical histories through Metriport. Metriport is the only open-source solution of its kind that offers all these integrations in a single platform, and standardizes complex data formats into industry standards such as FHIR and C-CDA. As a developer-first, HIPAA and SOC 2 Type II compliant interoperability solution, Metriport is powering the next wave of innovators in healthcare, creating an internet for healthcare data.

Liv Labs is a consumer healthtech company making modern solutions for incontinence. 29 million American women worry about leaking pee in public: an $8B market. Liv Labs is developing convenient self-care versions of proven-effective clinical treatments, including adaptive health coaching software and a novel continence pessary. Device inventor, Carly Price, reimagined the humble pillow for Casper and now leads digital retail design at Walmart. Company CEO, Melody Roberts, incubated digital service experiences now scaling globally at McDonald’s and Panera. We’ve raised $2.6M, including NIH and NSF grants, based on stellar effectiveness data and user feedback like, “With this, surgery is off the table.” US, European and Hong Kong utility patents have issued; Australia will soon. Our FDA-reviewed clinical trial launched at Northwestern University and continues at the OSU and UAB.

Current Description: RTHM provides virtual-first care for complex illness including Long COVID, ME/CFS, POTS, and mast cell activation. Many clinics focus on teaching patients how to better cope with symptoms, which is helpful, but we don’t stop there. We develop collaborations & partnerships so our patients access to the most promising testing and root-cause directed early therapies for their illness(es) with the goal of simplifying and streamlining the most efficient and effective clinical pathways so they can be scaled in the form of low cost online modules overseen remotely by clinicians. In conjunction with clinical care, RTHM operates a clinical lab and collects deep molecular data with robust clinical context to develop AI-powered diagnostics and better ways of predicting which treatments may work best for whom.

SmartSpot is a post Series-A stealth startup backed by Founders Fund and Khosla Ventures that uses computer vision to deliver an unparalleled fitness training experience to your home. Our unique hardware solution gives amazing trainers the ability to see their class participants in real time and deliver detailed advice that was previously only possible in person.

We are Pulse Active Stations Network and are setting up a network of connected IOT-enabled “Make in India” Smart Health Machines known as the Pulse Active Stations Network. We have conducted over 600,000 Health Check-ups and through our Pulse Active Station Smart Health Machines, we conduct mass screening for NCD risk factors such as Obesity, Hypertension and other factors to empower people to take informed decisions for theirs and their family's health.

BIOS Health was previously called Cambridge Bio-Augmentation Systems (CBAS) and focused on prosthetic neural interfaces as a first market. Now we use

Kips Health enables physical therapists to automatically collect RTM reimbursements with only 5 minutes of work.

We’re building the AI copilot for radiologists, powered by a foundational model for medical imaging. RadMate AI will read radiology images and generate full reports for radiologists to review and submit. Mohamed and Adam are technical co-founders who met while studying Computer Science at Cornell University. Before starting RadMate AI to solve the problems his dad faced as a radiologist, Adam worked at Palantir on the initial launch of Palantir’s Al Platform. Mohamed has experience at AWS, where his goal was to help enterprises innovate on the cloud, and PathAl, where he worked on their image viewer platform to improve the workflow of pathologists.

Float brings a nurse to your home when you’re sick. If you have a chronic illness, instead of making you come to an overcrowded hospital full of sick people, we bring the best of the hospital to you.

We are solving clinician staffing shortages for hospitals by automating routine patient-facing tasks.

Helping pregnant parents save the most personal source of stem cells - from their umbilical cord and placenta - to unlock future disease treatments. Offering cord blood banking, cord tissue banking, and placenta stem cell banking.

Ruth Health treats the 83% of post-pregnancy womxn who pee in their pants. We deliver 30-minute Postpartum Recovery + Training Sessions via telehealth, so moms around the globe with pelvic floor prolapse can get back to work, sex, and normal life—5x faster. Using conversational AI + biometric readings, Ruth Health will accumulate the largest, most diverse database in America on longitudinal maternal health

Reliance Health uses technology to make quality healthcare delightful, affordable and accessible in emerging markets. Through an integrated approach that includes affordable health insurance, telemedicine and a combination of partner and proprietary healthcare facilities, Reliance Health offers innovative healthcare solutions that meet the needs of emerging markets including Nigeria, Egypt and growing

We go to nursing homes, and we put an internet-connected bed sensor underneath all their beds. Our app gives nurses valuable insights and an overview of all their residents. We reduce fall incidents and bedsores while improving evening and night shift productivity by over 30%. Momo Medical solves the biggest problem affecting nursing homes, staff shortages while increasing the quality of care.

Loula is a software platform and national provider network for independent birth & postpartum doulas who accept Medicaid/Medi-Cal. Doulas typically operate outside of the traditional healthcare system and face an enormous learning curve and administrative burden when trying to accept insurance. This is why we created Loula. Starting with doulas in California, Loula handles their credentialing, contracting, and revenue cycle management so that they can focus on delivering the best quality care to their clients.

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Pelago, formerly Quit Genius, is the world’s leading virtual clinic for substance use management. We are transforming substance use support—from prevention to treatment—delivering education, management skills, and opportunities for positive change to members struggling with substance use, most commonly tobacco, alcohol, or opioids. Our solution gives employers the means to offer on-demand, personalized support to workers seeking to live healthier lives. Pelago’s cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) programs deliver convenient, accessible, and effective support that seamlessly integrates with health plans, pharmacy benefit managers, and wellness platforms. To date, Pelago has helped more than 750,000 members manage their substance use and improve their lives.

MentalHappy is a tele-health platform that allows health professionals to facilitate online support groups.The MentalHappy app allows health professionals to facilitate online support groups to help meet the rising demand for mental health services, create meaningful impact and earn extra revenue. Some groups are more intimate, while others have 100+ members, spanning different life events from grief support, healing from illness, life after divorce, black mental health, LGBTQIA+, stress management, emotional fertility support, coping with anxiety, and many other groups.

Fortuna Genomics employs methods from revolutionary genomics studies to non-invasively assess embryo traits, enabling parents to optimize their children's innate qualities without the need for gene editing. Through comprehensive genetic screening and forecasting, it empowers families to make informed decisions, optimizing their child’s well-being and capabilities from conception. With the convergence of advancements in genomic technologies, association studies, and sequencing efficiency, we are at a unique inflection point where such services can become widely accessible and impactful. Accurately predicting complex traits from genetic markers involves sophisticated models that must account for the interplay between countless biological and statistical factors. Our team is well-equipped to tackle this problem and make every parent's dream a reality by allowing them to give their children the best possible start in life.

Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.

In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics. The Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself. Our Solution: Digistain addresses this critical gap. Our technology transforms the current diagnostic process by enabling hospitals to analyze patient samples in-house using existing equipment, supplemented with our innovative technology. This approach offers near-instantaneous decision-making data, a stark contrast to the existing month-long waits. Central to our technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumour in the infrared spectrum, providing a personalized risk score. This score guides oncologists in selecting the most effective, individualized treatment plans, potentially reducing unnecessary chemotherapy and its harmful side effects. Impact and Potential: Our solution not only challenges the status quo in technology but also in accessibility. In a landmark government-commissioned study, Digistain demonstrated clinical evidence on par with the market leader, but at a fraction of the cost and time. Already making waves in clinical practice globally, with insurance reimbursement at leading cancer centers, our technology represents a paradigm shift in cancer care. Recognized by the Institute of Physics, the Royal Society, and Imperial College for our innovative contributions, and supported by entities like the NHS, Y Combinator, and the European Investment Bank, Digistain is more than a company—it’s a movement towards equitable, effective cancer treatment. With the potential to democratize access to life-saving diagnostics, Digistain is not just envisioning a better future for cancer patients; we are actively creating it.

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

38 million people suffer from heart rhythm disorders and are recommended to start medications that can save their lives, but require rigorous ECG monitoring to start and remain on these pills. SafeBeat Rx moves beyond diagnostics to guide these therapeutics, powered by our ML ECG software that integrates with existing FDA-cleared wearables to allow seamless physician approval of drug dosing, all from a mobile phone. We are a team of physicians, engineers, data scientists, and machine learning experts dedicated to using engineering to improve heart health.

At Diffuse Bio we’re building a push-button entirely AI software platform for molecular design, leveraging breakthroughs in generative AI. Our team has been behind breakthroughs in AI protein design for the past 6 years, including the first experimental validation of AI-generated proteins and diffusion models for protein structure and sequence.

Mederva Health helps hospitals & doctors in developing countries provide better care for their patients by tapping into the best US medical experts. Doctors abroad use our web app to consult with and learn from our board-certified physicians, like cardiologists and oncologists from Stanford, Harvard, and Johns Hopkins.

Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.

Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.

Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

We're building autonomous robots to make surgery more consistent, error free, and efficient. Nick is a 3x founder from medtech who co-founded a $1 billion company. Kartik is a 3x founder from autonomous vehicles who built and launched the world's first driverless truck. Surgical robotics companies are worth ~$200 billion total. AI will dominate the next generation of surgical robotics and we will be the first to build it. We're starting with a common urologic procedure that has by far the best outcomes but is not widely adopted due to technical difficulty.

Rebellyous Foods is a food manufacturing technology and production company defined solely to catapult meat alternative production toward price parity with animal-based meat. Rebellyous implements novel food manufacturing equipment and processes in large-scale production to produce low-cost plant-based meat at high volumes. These goals are achieved through uniquely designed food products, the use of high-throughput manufacturing automation and ‘smart’ production centers, and the development and utilization of new innovative low-energy manufacturing tools. Working closely with industry partners, Rebellyous makes plant-based meat sustainable, affordable, and widely available.

Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.

Dear Brightly offers prescription skin products online. Our mission is to get people access to the most effective, dermatologist vetted skincare products for healthy skin, using technology.

X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc

We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.

Delivery of TERT mRNA extends telomeres sufficiently in a few days to reverse over a decade of telomere shortening during normal aging. We are advancing TERT mRNA-based therapies to the clinic.

TrueClaim processes all payments between healthcare providers and companies that self-fund their insurance. Unlike incumbents, TrueClaim uses newly available data and AI to save companies 7% of their healthcare costs.

Astek Diagnostics is building a platform (Eugris) that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It is done by detecting the oxygen consumption of the bacteria

Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. Our team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.

We enable people to live their best lives. As we succeed, there is more convenience, healthier communities and thriving businesses. We get medications to those who need them and improve information, access and management of their care and enable businesses to move online and gain access to consumers who need their services

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

Selia Connects individuals and certified psychologists and psychiatrists with an online platform for one-on-one therapy delivered via video call. Selia offers convenient and affordable access to a fully-credentialed network of highly qualified providers while giving individuals self-guided tools, journaling and mood tracking to help them achieve their goals. We created Selia to address the unmet and growing demand for mental health services for Spanish speaking Latam everywhere. Our business-to-consumer (“B2C”) channel, made of individual consumers who pay directly to our platform, and our business-to-business (“B2B”) channel, that consist from start ups to enterprise clients such as Experian, Starbucks, Habi and more

The iSono Health platform combines automated 3D ultrasound technology with cloud computation and artificial intelligence to empower women and their physicians with early detection and monitoring of breast cancer. Our patented compact ultrasound scanner captures 3D images through automatic scanning of whole breast volume in 1 min. The device connects to a smartphone/tablet/laptop and is controlled by our mobile app. The data is transferred to a secure cloud for image processing and storage. Our machine learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expands ultrasound use in point-of-care diagnostics as well as monitoring of breast health at home, walk-in and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

Engage Bio is developing mRNA immunotherapies to defeat cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. Our approach is to provide cancer cells with instructions to make and gradually release our drugs within solid tumors. This local therapy allows us to eliminate tumors while sparing healthy distant tissues.

Almond is like One Medical but for women’s health: we make it easy to get great ObGyn care fast, both at our in-person offices and over telehealth. The problem with traditional ObGyn practices is that physician time is misused, so patients get slow care. We're rebuilding back-office tech that saves physicians time, and we're hiring a wider range of care providers roles, which let us deliver better outcomes to patients and reduce the amount of time it takes to get their issue resolved.

We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.

Memora Health helps healthcare organizations digitize and automate complex care workflows, making them simple for patients and clinicians to navigate. Memora ingests existing data on clinical workflows, converts them into cohesive messaging journeys that guide patients through their care episodes, and automates the completion of simple follow-up tasks in the EMR. Memora's platform reduces care team notifications by nearly 40%, has a >70 average NPS, and has improved clinical outcomes across various populations. Contact us at info@memorahealth.com

Eligible is the nation's first insurance billing platform built for builders. Founded in Mountain View California in 2011, Eligible's platform gives bootstrapping healthcare startups the scale of enterprise, and the Fortune 500s the agility of the hungry entrepreneur. Eligible has been listed as one of Business Insider’s 19 Hottest Startups to Watch and Katelyn has been featured in Forbes 30 Under 30 in Healthcare, Fast Company's Most Creative People in Business, and was named a Rising Star of Healthcare by Becker’s IT & CIO Review.

Akido is a care delivery platform focused on overcoming the complex needs of our most vulnerable populations. We are on a mission to leverage modern technology and proprietary datasets that have historically been locked up in our public health ecosystems in order to radically improve the quality of life and affordability of care for underserved people. We are a fast-growing, impact-focused, Y Combinator company being used nationwide to combat the Covid-19 pandemic, homelessness, and other public health crises. Across the country, health systems and government service providers use Akido to launch new technology-powered public health initiatives that improve the health and well-being of the communities they serve.

Brave Care is a group of kid-only primary & urgent care clinics that create a comfortable environment for little ones and reduce the stress and cost of emergency medicine for parents. We are 1/10th the cost of an ER trip and most often a visit can be completed in 1/4th the time. Common treatments: Pinkeye / Allergies / Tummy Bugs / Stitches / Broken Bones / Head Bumps / Sore Throats / Coughs / Fevers. Our digital services leverage our in-clinic medical professionals to reach across the country.

Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.

We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.

US hospitals and clinics are losing $125B every year due to delayed and inaccurate medical coding. Arintra is solving this problem by automating medical coding using AI and clinical NLP. Arintra converts a patient chart instantly into insurance claims with 96% accurate medical codes and zero human intervention. Arintra has processed more than 1.63 million claims this year across its 20+ provider clients that includes health systems and large physician groups. Through automation of these charts, Arintra has reduced undercoding by 11% and coding-related claim denials by 43%. Arintra is headquartered in Austin, Texas. Arintra is bi-directionally integrated with leading EHRs including Epic, Cerner, etc. to process patient charts directly from the EHR to create a direct-to-billing claim. This direct-to-billing claim includes precise E/M levels, CPT, ICD-10, HCC, HCPCS codes with appropriate modifiers and units. Both founders have PhDs in AI, significant ML and NLP experience, 60+ patents and publications, and a combined 20+ years of experience working at B2B companies and startups in Silicon Valley.

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.

Redcliffe Labs (a unit of Redcliffe Lifetech Inc) provides diagnostics with a comprehensive portfolio approach both with routine and specialised test menus with advanced testing labs all over India. Its digital first approach with on-demand 1-hour home collection and same day report is disrupting the way diagnostics is delivered today and thus is the fastest growing in India. Redcliffe Labs is providing 3500+ tests across its wide network of labs and collection centres. The company has served about millions of Indians and is processing more than 250K+ test parameters daily. The test portfolio is very wide including routine pathology tests, advanced genetic screening, research-based DNA tests in reproductive health, cancer and wellness/fitness. The easy to interpret smart reports provide key health check-points, which can help in diagnosing and treating both chronic and acute diseases on time. Redcliffe Labs has pioneered Drone technology adoption in the diagnostic sector by opening up the first commercial corridor from Uttarkashi to Dehradun. The company currently has 30+ labs and 700+ authorised collection centres in more than 120 cities across India. Redcliffe's vision is to provide world-class diagnostic services to people across the Indian sub-continent in an affordable manner.

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

SimplyInsured was founded with one mission: to eliminate fear from health insurance. By changing the way small business owners purchase health insurance with our 100% online platform, we’re transforming a $20 billion dollar industry and delighting thousands of customers. Our unique values-based culture (and extremely talented team) is our core competitive advantage, and each person on our team makes a direct, immediate impact on our business. We value transparency, feedback, bias to action, growth, and an obligation to dissent. Every opinion is respected, we hold each other to extremely high standards, we’re driven by the diversity in our backgrounds, and unified by 100% alignment on our mission. What’s best for the customer is the heart of everything we do, and our customer stories prove it: by changing health insurance we’re literally saving lives. Based in San Francisco, SimplyInsured was founded in 2012 and is back by Bessemer Venture Partners, Polaris Ventures, and Y-Combinator. If you’re up for the challenge of improving health insurance for millions of Americans, we’re just getting started, and we’re growing!

Shiok Meats is a cell-based clean meat company, exclusively working on seafood. Shiok Meats is the first cell-based meat company in Singapore and SE Asia and we employ cellular agriculture to grow seafood meat in the laboratory using cells instead of animals. Shiok in Singapore English slang means fantastic and enjoyable. Our meats are animal-, health- and environment-friendly with the same taste, texture and nutrients, but no cruelty. Our mission is to bring delicious and healthy meat by harvesting from cells instead of animals.

Have you ever wondered why it's so hard for physicians to communicate quickly and why the leading cause of preventable death is still a delay in communication? Our team has built the solution for this. Medigram is a team of tier 1 health system CxO IT executives, technologists, SaaS exec, physicians, engineers, and data experts. We have developed a breakthrough service for the medical industry to save lives and for hospitals to make millions per year. Medigram instantly flags insights from clinician chats for immediate insight into hospital operations and patient care. This reduces critical response times by 50%. We've designed this system to provide instant, reliable messaging (including images and audio files) across very complicated network environments in hospitals. Medigram is secure, designed for HIPAA, and a full stack system which includes database back end, middleware, logic, and client apps for iOS, Android, desktop, and the web. Our solution to this is Mobile Intelligence For Healthcare by providing a secure, intelligent workflow management platform for the patient care ecosystem and medical professionals. Within the healthcare environment, you have physicians, the patient care team, EMR, workflow, data, and administration which needs to be tied together with intelligence through Medigram.

At Curvenote we are building the communication and publishing tools for scientists and engineers. In the future, every scientific report will feature interactive graphs with live data that will make it significantly easier to share and reproduce the work.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.

BrainHi is an automated receptionist for local businesses. Local businesses are in search of new clients and revenue, yet 25% of phone calls to local businesses are missed and 80% of potential clients don’t leave voicemails. BrainHi uses AI to create an automated receptionist that answers missed calls 24/7 and chats with clients to schedule appointments and answer admin questions, resulting in more business. Cofounders Emmanuel and Israel started BrainHi after Hurricane Maria made communicating with doctors offices nearly impossible on the island of Puerto Rico.

Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.

H1 helps connect the healthcare ecosystem by providing a global platform of every healthcare professional and healthcare organization.

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

Lavo Life Sciences runs simulations of drug molecules on computers. Pharma companies use these simulations to guide their experiments and ultimately save time and money in the lab. This will de-risk and expedite clinical trials and FDA approval.

TYBR is developing a hydrogel to limit internal scarring after surgery. The naturally derived material is applied to coat tendons at the end of surgery to improve healing outcomes for the millions Americans who undergo tendon or ligament surgery each year.

We provides tools, data and systems to facilitate real-time insights, decluttering outbreak detection and enhancing risk mitigation. Our surveillance is used by industry, public heath and consumers globally.

MedPiper, a full-stack Diagnostics-as-a-Service platforms is working to ensure that health data is sourced via quality tests and made readily available. We have enabled payors and platforms obtain deeper insights into health, delivering better coverage and health outcomes. We're the equivalent of LetsGetChecked or IXLayer for India, ME and SEA. Aside from increasing test library, coverage delivery and CX by >200%, our clients are able to add new lines of revenue and expand LTV via deeper customer loyalty and higher personalisation contributing to increased customer engagement. We do this by offering full-stack, turnkey solutions for businesses to launch their own patient-centric lab testing programs. Based on the current demand, we see opportunities to sell into a diverse array of payors (insurers, corporate EB brokers), biopharma/CROs, employers, disease management platforms, OPD companies, public health agencies, consumer brands, and more. A few core things we deliver: - Easy integration (API-accessible), - A seamless experience (for all involved: patient, payor, provider, lab, mobile workforce), - A commitment to clinical quality standards, - Broad/deep test menu to service a diverse set of patients and medical needs.

Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.